These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 15476623)
1. Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. Rha SW; Kuchulakanti PK; Pakala R; Cheneau E; Fournadjiev JA; Pinnow E; Gebreeyesus A; Aggrey G; Wang Z; Pichard AD; Satler LF; Kent KM; Lindsay J; Waksman R Am J Cardiol; 2004 Oct; 94(8):1047-50. PubMed ID: 15476623 [TBL] [Abstract][Full Text] [Related]
2. Bivalirudin versus heparin as an antithrombotic agent in patients who undergo percutaneous saphenous vein graft intervention with a distal protection device. Rha SW; Kuchulakanti PK; Pakala R; Cheneau E; Pinnow E; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Lindsay J; Waksman R Am J Cardiol; 2005 Jul; 96(1):67-70. PubMed ID: 15979436 [TBL] [Abstract][Full Text] [Related]
3. Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents. Rha SW; Kuchulakanti PK; Pakala R; Cheneau E; Pinnow E; Gebreeyesus A; Aggrey G; Pichard AD; Satler LF; Kent KM; Lindsay J; Waksman R Cardiovasc Radiat Med; 2004; 5(2):64-70. PubMed ID: 15464942 [TBL] [Abstract][Full Text] [Related]
4. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results. Mishkel GJ; Moore AL; Markwell SJ; Ligon RW J Invasive Cardiol; 2007 Feb; 19(2):63-8. PubMed ID: 17268039 [TBL] [Abstract][Full Text] [Related]
5. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents. Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994 [TBL] [Abstract][Full Text] [Related]
6. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ; Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095 [TBL] [Abstract][Full Text] [Related]
7. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Lincoff AM; Bittl JA; Kleiman NS; Sarembock IJ; Jackman JD; Mehta S; Tannenbaum MA; Niederman AL; Bachinsky WB; Tift-Mann J; Parker HG; Kereiakes DJ; Harrington RA; Feit F; Maierson ES; Chew DP; Topol EJ; Am J Cardiol; 2004 May; 93(9):1092-6. PubMed ID: 15110198 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study). Dangas G; Lasic Z; Mehran R; Cox D; Ghali MG; Henry TD; Teirstein PS; Stella JF; Browne KF; Lewis SA; Knopf W; Leon MB; Moses JW; Stone GW Am J Cardiol; 2005 Sep; 96(5):659-63. PubMed ID: 16125490 [TBL] [Abstract][Full Text] [Related]
9. The use of bivalirudin to prevent subacute thrombosis during drug-eluting stent implantation. Medina RP; Foto D J Invasive Cardiol; 2004 May; 16(5):236-9. PubMed ID: 15152125 [TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009 [TBL] [Abstract][Full Text] [Related]
11. Bivalirudin: an anticoagulant option for percutaneous coronary intervention. Bates ER Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):153-62. PubMed ID: 15151464 [TBL] [Abstract][Full Text] [Related]
12. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study. Stabile E; Sorropago G; Tesorio T; Popusoi G; Ambrosini V; Mottola MT; Biamino G; Rubino P J Vasc Surg; 2010 Dec; 52(6):1505-10. PubMed ID: 20719465 [TBL] [Abstract][Full Text] [Related]
13. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ; J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319 [TBL] [Abstract][Full Text] [Related]
14. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. Allie DE; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Hebert CJ; Ellis SD; Mitran E; Chaisson G; Stagg S; Allie AA; Walker CM J Invasive Cardiol; 2003 Jun; 15(6):334-42. PubMed ID: 12777673 [TBL] [Abstract][Full Text] [Related]